Neurodol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neurodol

Property Description
Active ingredient Lidocaine Hydrochloride
Form Injectable Solution, Topical Preparations
Pharmacological class Local anesthetic
General purpose Targeted Pain Management and Anesthesia
Origin Synthetic Compound

Neurodol: Definition and Pharmacological Class

Neurodol is a specialized, single-component medicinal product whose therapeutic function is provided solely by the active ingredient, Lidocaine Hydrochloride. This substance is a well-established synthetic compound classified as a Local anesthetic. Its core purpose is to block the initiation and transmission of nerve impulses in a defined region of the body, a function clinically recognized across various countries. Lidocaine is established as an essential medicine, confirming its foundational role in clinical practice. The classification of this product as a Local anesthetic means it provides localized numbness or a reversible loss of sensation without inducing the systemic effects associated with general anesthesia.

Composition, Forms, and General Therapeutic Purpose

The Composition of Neurodol features Lidocaine Hydrochloride incorporated into a suitable pharmaceutical Base/vehicle. This allows the drug to be manufactured in various Dosage forms, primarily as an Injectable solution for Parenteral administration and as a Topical preparation for surface application. This formulation is often developed to be single-component, focusing exclusively on the anesthetic property of the Lidocaine itself, differentiating its use profile. This versatility is critical, as lidocaine hydrochloride is indicated for the production of local anesthesia by techniques such as percutaneous injection and nerve block, as well as via topical application to mucous membranes. This means the product can be used for temporary Anesthesia and targeted Pain management—for instance, to numb a small area of the skin before a minor surgical incision.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. WHO Essential Medicines List for Lidocaine

What side effects are possible with Neurodol?

Official Safety Profile and Adverse Reactions

The safety profile of Neurodol (Lidocaine Hydrochloride) is officially defined by the potential for dose-related systemic toxicity, meaning adverse reactions are primarily linked to the concentration of the active ingredient in the bloodstream. Systemic effects become apparent when plasma levels exceed a specific regulatory threshold.

Adverse reactions are classified by official regulatory bodies into specific System-Organ Classes (SOCs). The most commonly affected systems are the Central Nervous System (CNS), which may exhibit symptoms like dizziness, light-headedness, confusion, or even seizures; and the Cardiovascular System, with documented effects including bradycardia, hypotension, and, in severe cases, cardiovascular collapse or cardiac arrest.

Serious Adverse Reactions explicitly listed in regulatory documents include respiratory arrest, convulsions (seizures), and the potential for a serious hematologic condition known as methemoglobinemia. Allergic reactions, ranging from mild cutaneous issues to anaphylactic reactions, are documented but are officially classified as infrequent.

Population and Exposure-Related Considerations

The official labeling defines specific requirements for certain patient groups. For instance, reduced doses are necessary for the elderly, acutely ill, and debilitated patients. Patients with known hepatic or severe renal impairment also require increased caution, as their ability to clear the substance may be compromised, increasing the risk of accumulating toxic plasma levels. The label notes that repeated doses can lead to significant increases in systemic blood levels due to the slow accumulation of the drug or its metabolites.

Safety is formally restricted in individuals with a history of hypersensitivity to local anesthetics of the amide type and, for the intravenous form, in patients with severe, pre-existing cardiac conduction diseases like Stokes-Adams syndrome.

This structure ensures that the risk profile is understood as a function of exposure and patient specific factors, as categorized in government documents.

Overdose and Emergency Response

Overdose of Neurodol (Lidocaine Hydrochloride) is defined in regulatory documents by the onset of systemic toxicity affecting the Central Nervous System (CNS) and the Cardiovascular System.

Documented Manifestations

CNS toxicity progresses from early excitatory signs like tinnitus (ringing in the ears), lightheadedness, confusion, and muscle tremors to more severe, depressant outcomes such as convulsions, unconsciousness, and potential respiratory arrest. Cardiovascular manifestations documented in the official prescribing information include changes in heart rate, hypotension (low blood pressure), and the risk of severe events like cardiac arrest and cardiovascular collapse.

When Urgent Medical Help is Required

Regulatory guidance mandates that individuals seek immediate medical attention upon observing any sign of systemic toxicity or the specific, severe complication of Methemoglobinemia. This complication is visually identified by cyanotic skin discoloration (blue, gray, or pale appearance of the skin, lips, or nail beds). Immediate treatment is required to avert life-threatening cardiovascular and CNS consequences. Supportive care, including the use of resuscitative equipment and supplemental oxygen, is the primary management approach described in official documents. Furthermore, patients who are elderly, acutely ill, or have severe hepatic disease are noted in regulatory information to be at a higher risk of developing toxic blood concentrations.

Therapeutic Uses of Neurodol

The therapeutic domain for the active ingredient in Neurodol is centered on providing local or regional anesthesia and managing certain acute ventricular arrhythmias. These therapeutic applications are established for clinical use.

Targeted Uses and Patient Comfort

Neurodol is commonly used to provide targeted symptomatic relief from symptoms related to physical discomfort (like minor cuts, scrapes, or burns) and is relevant for managing symptoms that interfere with daily functioning. In clinical scenarios, it is considered relevant for the immediate prevention of sensation to facilitate medical or minor surgical interventions. This application is relevant when supportive symptom management is appropriate, assisting with conditions associated with acute or disruptive episodes.

The core therapeutic uses generally include being applied for the purpose of local anesthesia for procedural comfort, providing relief for minor surface pain, and the systemic management of specific ventricular tachyarrhythmias and certain instances of chronic neuropathic pain.

“The primary goal is providing supportive relief when symptoms interfere with routine activities, helping improve day-to-day comfort during symptomatic periods.”


Quick Fact: Relief for Localized Pain and Procedural Discomfort

For specialized applications, it may be part of symptomatic management for persistent symptoms of increased neurological activity, or it plays a role in managing acute symptoms linked to organ-specific functional stress in acute care settings. This diverse use profile supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Official Eligibility and Regulatory Restrictions

The eligibility profile for Neurodol (Lidocaine Hydrochloride) is strictly defined by regulatory authorities based on individual sensitivities and pre-existing conditions.

Absolute Contraindications

The medicine is contraindicated in any individual with a known history of hypersensitivity to local anesthetics of the amide type. For systemic (injectable) use, it is also contraindicated in patients with severe cardiac conduction defects, including Stokes-Adams syndrome or Wolff-Parkinson-White syndrome, or severe degrees of heart block absent a pacemaker.

Restricted and Conditional Use

Eligibility is restricted for patients with severe liver disease or kidney disease, as the drug’s metabolism and clearance may be impaired, which can lead to accumulation. Caution is required in acutely ill, elderly, or debilitated patients.

Age-Specific Rules

Official labeling indicates that the safety and effectiveness of the injection are not established in children younger than two years of age. For all elderly, debilitated, and pediatric patients, a dosage reduction is required commensurate with their physical status.

Pregnancy and Lactation Status

Neurodol is categorized as US FDA Pregnancy Category B and is not generally contraindicated for use during labor and delivery. During lactation, the drug is known to be excreted in human milk in low amounts, and caution is advised.

What should I know about interactions with other medicines?

Neurodol Interactions with other medicines and products

The official regulatory profile for Neurodol (Lidocaine Hydrochloride) identifies drug-drug interactions that primarily affect its systemic concentration and those that cause additive effects on the body's major systems.

Pharmacokinetic Interactions (Drug Clearance)

Neurodol is metabolized by the liver via the CYP3A4 and CYP1A2 enzyme pathways. Co-administration with medicinal products that inhibit these enzymes is documented in regulatory labeling as increasing the potential for elevated plasma concentrations of Lidocaine.

Interacting Product Category Example Medicines Listed in Labeling
CYP3A4 / CYP1A2 Inhibitors Cimetidine, Amiodarone, Fluvoxamine, Beta-Adrenergic Receptor Blockers

These interactions are formally noted to decrease the systemic clearance of Neurodol, with Cimetidine specifically documented to reduce clearance by approximately 25%. Monitoring for signs of accumulation is required with these combinations.

Pharmacodynamic Interactions (Additive Effects)

Interactions that reinforce the effects of Neurodol on the body are noted in official warnings:

  • Class I Antiarrhythmics: Co-administration with other Class I agents (e.g., Mexiletine) may produce additive systemic toxic effects, particularly concerning the cardiac and central nervous systems.
  • Other Local Anesthetics: Using Neurodol with other local anesthetic agents creates a risk of additive systemic toxicity due to combined effects on neuronal activity and cardiac function.

Population-Specific Notes

The regulatory profile highlights caution for elderly patients and those with hepatic impairment. These populations are noted to have a naturally reduced intrinsic clearance of the medicine, making them more susceptible to the rise in plasma concentration when co-administered with interaction-causing substances.

Mechanism of Action

Targeted Blockade of Voltage-Gated Sodium Channels

Neurodol's mechanism centers on the selective blockade of voltage-gated sodium channels (Na^+ channels) located within the membranes of peripheral nerve axons. The active substance, after gaining access to the nerve's interior, physically binds inside the channel pore when it is in an open or inactivated state. This interaction acts as a physical barrier, preventing the rapid influx of sodium ions required for depolarization. This molecular action directly and reversibly inhibits the nerve's capacity for action potential propagation.


Use-Dependent Suppression of Nerve Conduction

This mechanism is use-dependent, meaning the blockade is preferentially enhanced in nerve fibers that are already active, such as those involved in conduction in peripheral afferent fibers. By inhibiting the flow of Na^+ ions, the drug prevents the generation of the action potential, thereby disrupting action potential sequences before they can reach the central nervous system. The physiological result is a localized and temporary stabilization of the nerve membrane, resulting in an absence of signal transmission in the targeted area.

Dosage and Administration Information

How to Use Neurodol — Administration Standards

Administration of Neurodol, which contains Lidocaine Hydrochloride, is governed by pharmaceutical standards defining the route, dosing limits, and required procedural context. The drug is administered either by parenteral injection (e.g., nerve blocks, infiltration, intravenous infusion) or by topical application to mucous membranes, such as in the urinary or respiratory tracts.

Dosing and Frequency Limits

Established protocols define specific maximum dose thresholds. For local and regional anesthesia, the maximum single recommended dose of lidocaine without epinephrine should not exceed 4.5 mg/kg of body weight, with a general total maximum of 300 mg. When used with epinephrine, the limit is increased to 7 mg/kg of body weight, generally not exceeding 500 mg.

  • Acute IV Use: For antiarrhythmic therapy, the IV administration typically begins with a bolus dose of 50–100 mg. This may be followed by a continuous maintenance infusion, usually at a rate of 1–4 mg/minute. The maximum recommended dosage for continuous blocks, such as epidural or caudal, should not be repeated at intervals of less than 90 minutes.

Administration Requirements

Proper use requires adherence to specific protocols based on the setting and route. Preservative-free formulations are utilized for central neural blocks (spinal/epidural). Procedures requiring injection necessitate slow, incremental doses with frequent aspiration to avoid unintended intravascular administration.

Dosage adjustments are indicated for specific populations. Reduced doses are utilized for older adults, debilitated patients, and those with hepatic or cardiac impairment, reflecting altered clearance and systemic tolerance. Pediatric dosing is also reduced and determined based on the child's age, weight, and physical condition.

Recent Clinical Evidence

Research evidence / Overview of studies for Lidocaine Hydrochloride


Evidence for Use in Local Anesthesia (Injectable)

The research on Lidocaine Hydrochloride as an injectable local anesthetic was examined using Randomized Controlled Trials (RCTs) and comparative clinical studies. This research explored its use in adult and pediatric populations requiring localized numbness for temporary periods, such as for minor surgical procedures or dental work. Research examined how quickly complete loss of sensation was observed and the observed duration of the sensory block. Findings describe patterns observed in the studies related to the onset time and the duration of the anesthetic block. Research for this acute use is based on a large volume of historical study designs, and long-term effects are not fully established for this acute application.


Evidence for Topical/Dermal Analgesia (Surface Application)

The research on Lidocaine Hydrochloride in topical preparations for application to the skin's surface was studied in research exploring outcomes related to physical discomfort. Research often involved systematic reviews and trials to assess the use of creams or patches for minor surface injuries or for use prior to procedures like venipuncture. The findings describe patterns observed in the studies that relate the formulation of the product to the consistency of the surface numbing. Evidence quality varies across studies, and data for certain groups remain insufficient or limited.


Evidence for Acute Arrhythmia Management (IV Use)

The research on Lidocaine Hydrochloride as an intravenous solution was evaluated in specific populations with systemic or functional imbalance, namely those experiencing acute, unstable ventricular heart rhythms. These studies examined outcomes such as the resolution of the irregular rhythm and survival in acute settings. The research describes how the drug was studied within acute-care protocols for managing these cardiac events. The evidence base for using the drug prophylactically (preventatively) has been observed in some studies to be inconsistent or mixed.


Research Gaps and Uncertainty

While the anesthetic and acute cardiac uses are well-characterized, several areas have evidence quality that varies across studies. For instance, the research exploring the use of Lidocaine Hydrochloride as a continuous intravenous infusion alongside traditional pain management post-surgery has produced mixed findings for outcomes beyond the measured changes in the amount of opioid pain medication required. Comparative evidence is not consistently available in some contexts, and overall, sample sizes were modest in some specialized studies.

Key Studies & References World Health Organization (WHO) Model List of Essential Medicines

Frequently Asked Questions (FAQ)

Common questions about Neurodol (FAQ)


Q: Is Neurodol a type of painkiller?

Neurodol’s active ingredient, Lidocaine, belongs to a class of medicines called local anesthetics. Its mechanism involves temporarily blocking electrical signals in the nerves to cause numbness in a specific, targeted area. This action disrupts the transmission of pain signals, which is why it may provide relief from physical discomfort.


Q: Can Neurodol be taken for any kind of nerve pain?

Official documentation indicates that Neurodol is approved for specific uses, such as achieving localized numbness for minor procedures and managing certain acute heart rhythms. It is not generally indicated or approved for the treatment of all types of generalized or chronic nerve pain across the body.


Q: Will Neurodol make me feel sleepy or tired?

Yes, official labeling documents list drowsiness as a reported Central Nervous System (CNS) side effect. It is also noted in regulatory documentation that drowsiness can be an early indication that the level of the drug in the bloodstream may be higher than intended.


Q: Is it normal to have mild headaches when starting Neurodol?

Headache is listed in regulatory documents as a potential adverse reaction reported following the use of the medicine. This is particularly noted in official summaries concerning certain forms of administration, such as spinal anesthesia.


Q: Can Neurodol be taken with common over-the-counter pain relievers?

The official label focuses on specific drug-drug interactions, particularly those that affect Neurodol's concentration or heart function. However, the use of Neurodol alongside other products that contain local anesthetic agents, including some over-the-counter topical products, is noted to increase the risk of combined toxic effects.


Q: How long does the effect of one dose of Neurodol typically last?

The duration of the effect varies significantly based on the specific formulation and the route of administration. For example, for the intravenous (IV) bolus form used to manage acute heart rhythms, the clinical pharmacology section describes the effect as lasting approximately 15 to 20 minutes.


Q: Are there specific foods or drinks to avoid while taking Neurodol?

While the primary regulatory label focuses on interactions with prescription drugs, some aggregated medical information suggests that foods like grapefruit juice may influence the blood levels of the active ingredient. Specific guidance regarding diet and Neurodol is generally managed by the healthcare provider.


Q: Can young adults or teenagers use Neurodol?

Official labeling documents state that for pediatric use, the dosage must be reduced and carefully determined based on the child’s age, weight, and physical condition. Regulatory documents indicate that safety and effectiveness have not been established for all age groups or formulations.


Q: Does Neurodol have a black box warning?

Yes, specific formulations of the active ingredient, such as the oral viscous solution, carry a BOXED WARNING. This is the strongest warning required by the FDA and concerns the risk of life-threatening events when the medication is used improperly, especially in infants and young children.


Q: How is Neurodol different from an opioid?

Neurodol is classified as a local anesthetic that works by stabilizing the nerve membrane and blocking the transmission of electrical signals. This mechanism is fundamentally distinct from opioids, which act on receptors in the central nervous system to alter the perception of pain.


Q: Can Neurodol affect my ability to drive or operate machinery?

The official safety profile reports potential Central Nervous System side effects, including confusion, dizziness, and drowsiness. These potential effects may have the potential to impair coordination and judgment.


Q: Is Neurodol suitable for people with pre-existing kidney issues?

Official documentation advises caution and possibly reduced doses for patients with severe renal (kidney) impairment. This is because the kidneys play a role in eliminating the drug's byproducts, and impairment could lead to the accumulation of toxic levels in the body.


Q: Is Neurodol safe to use during pregnancy (in general terms)?

Regulatory documents recommend use during pregnancy only if the potential benefit is determined to justify any potential risk. Local anesthetics are known to rapidly cross the placenta, and the effects on the fetus have been part of regulatory review.


Q: Does official information suggest any monitoring is needed while on Neurodol?

Yes, for certain applications, such as intravenous administration for acute heart rhythms, continuous monitoring of blood pressure and the electrocardiogram (ECG) is described as essential. Monitoring for signs of drug accumulation may also be necessary when Neurodol is combined with certain interacting medicines.


Q: Can Neurodol affect mood or cause anxiety?

Official documentation lists certain Central Nervous System effects that have been reported, which include nervousness, apprehension, and euphoria. These effects are generally listed in the regulatory documents as Central Nervous System (CNS) effects.


Q: Does Neurodol interact with common supplements like vitamins or herbal remedies?

The official label's interaction section primarily addresses prescription medicines that affect the drug's metabolism. However, warnings have been issued for certain topical forms noting that interactions with dietary supplements are possible. Full disclosure of all products being used assists healthcare providers in assessing potential risks.


Q: How should Neurodol be stored?

Official documents require that Neurodol be stored at Controlled Room Temperature (CRT), which is typically defined as 20 C to 25 C (68 F to 77 F). The product must be handled according to instructions to maintain its stability and effectiveness.


Q: What is the general duration of treatment described for Neurodol?

Based on its approved uses, Neurodol is generally described for temporary, short-term treatment. Its indications include providing localized numbness for a procedure or managing acute instability in heart rhythms.


Q: What makes Neurodol a regulated medicine?

Neurodol is classified as a regulated medicine because its active ingredient, Lidocaine Hydrochloride, is subject to specific approval, classification, and continuous safety oversight by government bodies such as the FDA and EMA. This regulation ensures its documented use and safety profile.


Q: Is Neurodol described as a prescription-only medicine?

Many of the drug's high-concentration forms, including injectable and oral viscous solutions, are classified by regulatory bodies as prescription-only medicines (Rx Only). This classification is due to the potential risk of systemic toxicity if administered incorrectly.


Q: What is the research evidence for Neurodol's use in non-nerve pain conditions?

Official research evidence exists for the intravenous use of Neurodol in the management of acute, unstable ventricular heart rhythms. This use is for systemic or functional heart imbalance and is separate from its indication for local nerve blockade and pain management.


Q: What does 'not recommended' mean for certain patient groups using Neurodol?

The regulatory phrase 'not recommended' generally indicates that the product's risks in that specific patient group, such as certain ages or co-morbid conditions, have been found to outweigh the known benefits. It may also signify that sufficient safety data is not available for that population.


Q: Are there any known issues with taking Neurodol before or after surgery?

Neurodol is indicated for use during certain surgical and dental procedures to produce localized numbness. Official warnings highlight that the combined use of other local anesthetic agents around the time of the procedure creates a risk of additive systemic toxicity.


Q: Does Neurodol work on all types of pain signals?

The mechanism of action involves blocking voltage-gated sodium channels in nerve axons. By preventing the flow of sodium ions, the electrical signal (action potential) is inhibited, resulting in a temporary block of signal transmission in the targeted nerve fiber.


Q: Why do doctors adjust the dose of Neurodol over time?

Official labeling documents require dosage adjustments for specific groups, including older adults, debilitated patients, and those with impaired liver or heart function. These adjustments are necessary to account for potential differences in drug clearance and systemic tolerance.


Q: Is it possible to be allergic to Neurodol?

Yes, official documentation lists a known history of hypersensitivity (allergic reaction) to local anesthetics of the amide type as a contraindication. While reported, severe allergic reactions, including anaphylaxis, are officially classified as infrequent adverse reactions.


Q: What happens if I stop taking Neurodol suddenly?

Warnings in the official labeling for the intravenous form focus on the need for prompt cessation in cases of toxicity or excessive depression of cardiac conductivity. There are no reported withdrawal symptoms or effects from sudden cessation described for this drug in its regulatory profile.

How should Neurodol be stored and disposed of?

Neurodol (Lidocaine Hydrochloride) must be stored and disposed of according to the requirements stated in the official regulatory labeling to maintain stability.

Required Storage Conditions

  • Temperature: Store at Controlled Room Temperature (CRT), typically 20 C to 25 C (68 F to 77 F). The product must be protected from light and must not be frozen.
  • Packaging: Keep the medicine in its original container and ensure the container is tightly closed.
  • Child Safety: The medication must be stored out of the sight and reach of children.

Disposal Instructions

  • In-Use Stability: For single-dose injectable forms, any unused portion must be discarded immediately after initial use due to sterility requirements.
  • Disposal: Unused or expired medication must be disposed of according to local regulations. Consumers are advised to utilize a drug take-back program where available, rather than disposing of the product in household waste without proper preparation or flushing it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neurodol found in:

A-Z Index: